SARS-CoV-2 and COVID-19 Research

This paper develops a biophysical model to predict the fitness of SARS-CoV-2 variants based on RBD binding thermodynamics and epistatic interactions.

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

This study shows that p38-MAPK is essential for SARS-CoV-2 replication, as its inhibition reduces viral growth and its activation supports RNA/protein synthesis without affecting viral entry or budding.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

This study shows that SARS-CoV-2 ORF8 protein modulates lung inflammation and disease severity in mice by affecting macrophage infiltration and function.

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

This paper develops a mutant ACE2 that neutralizes SARS-CoV-2 in vivo through aerosolized delivery, demonstrating its protective effect in a mouse model.

This study investigates the virological properties of the SARS-CoV-2 KP.2 variant, finding it has higher viral fitness and immune resistance compared to JN.1, contributing to its rapid spread.

The paper uses a pseudotyped virus infection assay to assess how SARS-CoV-2 variants interact with ACE2 receptor variants across species, revealing structural and compatibility shifts.

This study compares neutralizing antibody titers in human and hamster sera against SARS-CoV-2 variants using a live-virus neutralization assay, finding hamster sera show higher reactivity.

This study investigates the interaction between SARS-CoV-2 Nsp9 and nanobody 2NSP90 using NMR spectroscopy and molecular dynamics simulations, revealing stoichiometry and epitope details.

This study uses high-throughput screening to identify small molecule inhibitors that block coronavirus entry, finding a novel broad-spectrum antiviral.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

This study uses deep mutational scanning to analyze the SARS-CoV-2 spike fusion peptide, identifying mutations affecting viral entry and antibody resistance.

The paper compares glycosylation and structural changes between SARS-CoV-2 Omicron and D614G spike proteins, finding increased surface accessibility in Omicron due to altered glycosylation.

The paper compares antibody responses from individuals with XBB reinfection and those vaccinated with WSK-V102C, showing the vaccine induces stronger neutralization against SARS-CoV-2 variants including JN.1 and BA.2.87.1.

The paper describes the scalable production and purification of SARS-CoV-2 nucleocapsid proteins in E. coli and evaluates their use in ELISA assays.

This study investigates the virological traits of the SARS-CoV-2 BA.2.87.1 lineage, finding it efficiently enters human cells but is more sensitive to antibody neutralization than JN.1.

This study develops a live-attenuated SARS-CoV-2 vaccine candidate, BK2102, which induces long-term immunity and is safe in animal models.

This paper models viral resistance emergence in SARS-CoV-2 treated with anti-spike monoclonal antibodies, showing that target cell replenishment mechanisms can explain high viral rebounds.

This study compares two plant-derived Hsp90 adjuvants, showing that rNbHsp90.3 induces stronger neutralizing antibodies and different cytokine profiles than rAtHsp81.2 when used with SARS-CoV2 RBD antigen.

This study shows SARS-CoV-2 infection activates inflammatory macrophages in vascular immune organoids, upregulating interferon signaling linked to cytokine release syndrome.

This study assesses the antigenic properties and immune evasion of the SARS-CoV-2 variant BA.2.87.1, finding it less resistant to neutralizing antibodies than JN.1 but with compensatory deletions in the NTD.

This paper identifies small molecule inhibitors of SARS-CoV-2 Mac1 that inhibit coronavirus replication, validating Mac1 as an anti-viral target.

This study identifies two double mutations in SARS-CoV-2 3CLpro that confer resistance to the non-covalent inhibitor WU-04 and reveals trade-offs between catalytic activity, thermostability, and drug resistance.

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

This study compares immune evasion, antigenicity, and cell-cell fusion properties of SARS-CoV-2 BA.2.87.1 and JN.1 variants, finding BA.2.87.1 shows less neutralization escape and higher infectivity than JN.1 and XBB.1.5.

This study investigates the assembly of SARS-CoV-2 nucleocapsid protein with nucleic acids using biophysical techniques and mutant proteins, revealing key interaction motifs and stabilization mechanisms.

This study presents cryoEM structures of SARS-CoV-2 Nsp15 bound to dsRNA, revealing how it recognizes and cleaves poly(U) tracts to evade host immunity.